Pulmonary hypertension (PH) is a complex and often misunderstood condition, with significant implications for patient morbidity and mortality. This article aims to provide a comprehensive review of the fundamentals of PH for healthcare professionals.
PH is defined as an increase in mean pulmonary arterial pressure ≥ 25 mmHg at rest, as assessed by right heart catheterization. The World Health Organization (WHO) classifies PH into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy.
Regardless of the cause, the pathophysiology of PH involves three main pathways: vasoconstriction, vascular remodeling, and thrombosis. These processes lead to increased pulmonary vascular resistance, right ventricular overload, and ultimately, right heart failure.
PH often presents with nonspecific symptoms such as dyspnea, fatigue, and syncope, making diagnosis challenging. A high index of suspicion is necessary, particularly in patients with risk factors such as connective tissue disease, congenital heart disease, and chronic lung disease.
The diagnostic evaluation of PH involves a combination of clinical assessment, echocardiography, and right heart catheterization. Additional tests may include pulmonary function tests, CT scan, and ventilation-perfusion scan to identify the underlying cause.
Treatment of PH is guided by the underlying etiology and the severity of disease. Strategies include general measures, targeted drug therapy, and in severe cases, lung transplantation. Early diagnosis and treatment can significantly improve patient outcomes.
In conclusion, PH is a complex condition requiring a multidimensional approach for diagnosis and management. Healthcare professionals must have a sound understanding of the fundamentals of PH to provide optimal care for these patients.
1.
The White House has postponed its plan to outlaw menthol cigarettes indefinitely.
2.
Study Finds Actionable Mutations in Brain Mets of Breast Cancer Patients
3.
Distinct results for patients with positive and negative pancreatic cancer who are treated with systemic therapy, chemotherapy, and radiation.
4.
Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.
5.
Frontline Mosunetuzumab Shows High Response Rates in Follicular Lymphoma
1.
Understanding the Importance of Knowing Your MCV Normal Range
2.
Modern Concepts in Oncology Across Clinical Settings
3.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
4.
Strategic Deals and FDA Approvals Transforming U.S. Oncology Drug Development
5.
Metabolic Reprogramming of the Tumor Microenvironment: Mechanisms, Clinical Relevance, and Emerging Therapeutic Strategies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
3.
From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation